LX16061207BTC: A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of XERMELO® (telotristat ethyl) plus First-line Chemotherapy in Patients with Unresectable, Locally Advanced, Recurrent or Metastatic Biliary Tract Cancer (BTC)